Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Shorting any stock comes with increased cost and risk. It has potential to make some money. However, shorting a stock, has the potential to turn even a large fortune into a small fortune. Panic attacks, although damaging, don't last. Those at the top of the cartel make some quick money then move on to try to spook another group of stockholders. The anonymous "Pumper Stopper" won't reveal his or her identity. That in itself is revealing.
I added shares yesterday afternoon as well.
As opposed to a class-action against the company. The company and the stockholders should investigate bringing a suit against "Pumper Stopper", the anonymous author, and SA? Publishing such an article anonymously is a cowardly thing to do. What is more, it is reckless and irresponsible. It is a definite reflection on what the author thought was the truth about this company as it exists today as opposed to how it existed in the past. The article is irrelevant to the company as it exists today.
Yes, weak and unprofessional with some awful made up pics/graphics from a position of hiding behind the name "Pump Stopper".
Who is the person that wrote the SA article? Will that person provide us detailed information about themselves so we may know the truth about that person. Publish truthful information about himself or herself so we will know about that person. "The truth will set you free" quotes the "The Pump Stopper". Publish the truth about your self "Pump Stopper". That will make us free.
I am long the stock and buying more this afternoon. I have researched and followed this company for a very long time. I have confidence in the company and its products. Some SA authors are sincere. Some are not. I am not swayed by the article. I will not follow the herd.
Short seller networks or cartels to speak have existed for eons. Members include financial for profit authors, people that spread uncertain or doubtful or outright false "truths", and others. Some are well organized. Some of the leaders are very smart. They trick and scare people, the herd, into following them. They understand and exploit the herd instinct. They boast about making money. Start-up companies, even those with promising products, are often targets. These people don't care about the truth. They do this repeatedly. They brag about having a number of followers. Those that orchestrate this practice often profit. Unfortunately, many in the herd get trampled while those at the top of the nefarious group profit. I feel sorrow for those in the herd that get hurt. Some shorts that have come and gone from this board have touted the number of followers they have.
Next time.
That is frustrating. Well, maybe Mike will take some Anavex 2-73 or 273-plus and remember time.
Nitwit!
If persistent, with a great deal of work you may over time turn a small fortune into a large fortune. With AVXL, a very unusual situation, you may turn a little amount of money into a fortune.
Shorting any stock comes with increased cost and risk. It has potential to make some money. However, shorting a stock, such as AVXL, has the potential to turn a large fortune into a small fortune.
If he and others like him were interested in the science, he would comment on that instead of fanning the flames for "another concerted short effort here". Instead, he comments in short syllable tweets that reveal nothing of any real value.
It is my hope that you do very well. The best of luck to you, Anavex, and the science. Society in general needs the Anavex drugs to succeed. The more successful the better.
Simple. That's how markets work. There's lots of willing buyers and a lack of willing sellers.
A common tool shorts use to spook the market is to spread dilution misinformation.
Brilliant. Simply brilliant. Plus, all of this speaks well for the science, which looks promising to a firm that has the confidence to do this deal.
Very honorable! Just an honest mistake. Thank you.
Very good. And yes, the FDA is clearly open to considering new biomarkers to speed drug development. The FDA has a Biomarker Qualification Program:
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm284076.htm
Subsequent to up-listing, numerous examples of positive stock performance exists. The timing could not be better, I believe. Assuming November 7 positive news and scientific publication of that news, we should see a strong move up based on the Blockbuster potential for Anavex therapeutics. The indications are that the clinical trial will report improved performance, correct? Knowing what I have learned, in no way would I be selling this stock.
Truly Sherlockian. I think you solved our mystery. A keen intellect endeavor, indeed. The presentation will be positive, and the JPAD will spread the word well beyond Barcelona. What is more, is it should give Anavex (AS IT EXISTS TODAY MR. WARD) the respect it deserves.
I agree. Excellent. Thank you.
Didn't the listing approval come late Friday? Perhaps there was not much awareness while the stock was still trading. However, look at Friday's chart. The stock gained back a lot of lost territory in the afternoon. I believe the down days during the week were due to short attacks. It might help if you took a look at Clay Trader's chart video for Friday.
Off label? Once a drug has an approval by the FDA a physician may prescribe the drug off label - meaning for a disease for which the drug is not labeled. It is illegal for a company to promote a drug off label though. It would also be illegal for a human to be administered any drug that does not have FDA approval.
Yes, the pressure is on for the FDA to embrace biomarkers and end points.
The 21st Century Cures Act (HR 6), if passed by Congress supposedly would quicken the pace of approval for badly needed drugs. The legislation also clears the way to use new and creative adaptive trial designs and deploy the most modern statistical and data tools. Subtitle B of Title II is slightly modified from the original draft of the legislation. It remains focused on the "qualification and use of drug development tools"—an area which has attracted significant attention from legislators in recent months. The hope is that FDA can rely on biomarkers and other surrogate endpoints to accelerate the approval of some new products for high-need populations.
"The development of biomarkers and other drug development tools can benefit the availability of new medical therapies by helping translate scientific discoveries into clinical applications," the bill explains.
The bill calls on FDA to promote the development and qualification of biomarkers by issuing new guidance documents regarding the standards for qualifying biomarkers, and to establish a process by which biomarkers can be qualified.
Interestingly, FDA already maintains a program which would appear to do exactly as Congress has asked for in its bill. The agency's Drug Development Tools Qualification Program, for example, is intended to accelerate drug development by focusing on qualifying relevant biomarkers. A 2014 guidance document, Qualification Process for Drug Development Tools, describes the process by which FDA qualifies these tools. In addition, a new guidance document released to the public in March 2015 clarifies FDA's Critical Path Innovation Meetings process, at which FDA dispenses advice on the development of biomarkers, clinical outcome assessments, natural history designs and new technologies.
Accelerated Approval: Section 2022 of the draft legislation would amend federal law to facilitate accelerated approvals—approvals based on surrogate (e.g. intermediate) endpoints intended to serve as evidence that a drug would be effective in a population. FDA has long relied on surrogate endpoints to support accelerated approvals, but only for drugs intended to treat patients with life-threatening illnesses and unmet needs.
See more at: http://www.raps.org/Regulatory Focus/News/2015/04/30/21192/Regulatory-Explainer-The-Updated-21st-Century-Cures-Act/#sthash.lioPBhF3.dpuf
Forget for a moment what is said by financial for profit authors, people that spread uncertain or doubtful or outright false "truths," and those that are inclined for whatever reason to shout fire in a crowded theatre to create a panic. Instead, take a look at what those whose purpose is to find a treatment or cure for CNS diseases and cancer that Anavex's drug candidates target. Among these are the Michael J. Fox Foundation and the Roskamp Institute. Do your individual research and reach your conclusions about whether these people have expressed confidence in Anavex's therapeutic approach. By way of only one example, you may find that Fiona Crawford, PhD, President of The Roskamp Institute, said, “ANAVEX PLUS has shown promising pre-clinical data and represents a novel approach for the treatment of Alzheimer's disease, and we are excited to work with the Anavex team.”
Additionally, research the science as others on this board has done, and consider the members of Anavex's Scientific Board, their professional backgrounds in treating diseases, and credentials.
Reach your own conclusions based on sound factors not faulty logic such as sighting one drunk on the street of a small town as a basis for concluding that the entire town is one of drunks or that one scoundrel was associated with the shell company years ago, therefore, the company to this day must be rotten.
Great! I added again today as well.
Get this! I wonder if Turing's CEO, Martin Shkreli, is one of these better know short sellers of other biotech stocks? Put the latter together with the despicable price hike by Turing of a life saving drug. Consider the damage that Turing did to all biotech companies with the enormous overnight price hike of this drug. Turing's actions, whether intentional or not, brought forth an overnight political attack on all biotech companies that resulted in huge market losses. I am curious about Turing's overall motives? The latter is where the focus should be -- not on all biotech companies -- but on Turing and its CEO.
Short seller networks or cartels to speak have existed for eons. Members include financial for profit authors, people that spread uncertain or doubtful or outright false "truths", and others. Some are well organized. Some of the leaders are very smart. They trick and scare people, the herd, into following them. They understand and exploit the herd instinct. They boast about making money. Start-up companies, even those with promising products, are often targets. These people don't care about the truth. They do this repeatedly. They brag about having a number of followers. Those that orchestrate this practice often profit. Unfortunately, many in the herd get trampled while those at the top of the nefarious group profit. I feel sorrow for those in the herd that get hurt. Some shorts that have come and gone from this board have touted the number of followers they have. When that happens, I am reminded of the followers of Jim Jones, who led over 900 of his followers to travel to Jonestown, Guyana and commit suicide.
I added to my position today. Despite the move down the last few days, fundamentally nothing has changed. The multi-billion dollar potential for Anavex drugs is still there. I believe that the up-listing will mean a much larger shareholder base and more exposure for this broader base to consider Anavex’s prospective groundbreaking drug therapy. Alzheimer’s therapies alone will grab much attention, not to mention Parkinson’s disease, etc. Lastly, Clay Trader after the close today presented his chart, which he says is a “beautiful” over-all long term chart. Long term it looks like a beauty to me as well. Once again, I am glad I added to my position.
IP: Thanks. I have decided not to do it. I see it as counterproductive. Besides, I like to feel good about what I do, and I would like for Anavex to be a success. Making my shares available to be sold short goes against the grain.
JB: Thank you.
Securities lending market for AVXL. While driving across Texas today, which by the way is a very long drive, I received a call about one of my accounts. The brokerage firm for this account proposed that I grant permission to lend my shares to generate revenue that would be split 50/50 between me and the brokerage firm. I was told this: "... the potential revenue in your account is primarily stemming from your position in AVXLD, which is a valuable position in the securities lending market right now."
I did not commit. I am curious, however, and thought I would ask members of this board about their thoughts? What about that latter statement or quote re an AVXL paid for long position being valuable in the securities lending market "right now"? What does anyone think the shorts have in store? Why are AVXL shares valuable in the securities market?
Yes, thank you. Good work.
Whiskysausage: Thank you, and ditto all of the compliments you have deservedly received.
That's a much better strategy. Keeping some is a very good idea.
Apparently, you have not been reading about all the other positive catalysts in store for AVXL besides the November 7
presentation.
Price/volume activity for AXON is bearish. AXON is trading on relatively low volume and has underperformed consistently over the past six months. What's more, fundamentally, what is there to reverse the price/volume activity for AXON, and what is on the horizon to move AVXL price and volume higher? Compare the activity of AVXL to AXON.
There is nothing else in the AD biotech area that comes close to AVXL. If anyone disagrees, I am open to specifics and their suggestions.
I agree. Price/volume activity for AXON is bearish. AXON is trading on relatively low volume and has underperformed consistently over the past six months. What is more, fundamentally, what is there to reverse the price/volume activity for AXON? Compare the activity of AVXL to AXON.
Greenspam and George: Thank you for the excellent research and information. Anyone considering selling should read this first. By the way Barron's article this weekend:
I thought you would be interested in the following story from Barron's
"It’s Not Easy Being a Short These Days"
http://www.barrons.com/articles/its-not-easy-being-a-short-these-days-1445056968
Shorts use to earn interest on their funds deposited to short stocks - not now courtesy of the fed. Now they receive no interest and the fees for shorting are much higher, as has been discussed on in the article and on this board. And yes, the tax rate on short term gains, if any, are greater. However, the real risk is the loss that a short term trader may suffer in shorting Anavex in the face of all of the sound fundamentals and news due in the next 15 trading days regarding up-listing, clinical trials, etc.
Sent from my iPad
Whether the article is new or old, one thing I have to give Jimmy credit for is he cautiously ended his article about selling saying: "It's also worth adding this near-term bearish outlook in no way is a long-term judgment call on the company's pipeline. It's just a short-term trading call driven by the rapid runup in the price of the stock. Once a bottom is made and the bulls start to sniff around again, there's enough of a story here to wade back in, looking for the next such advance from AVXL."
He is definitely correct about looking for the next AXVL advance. However, remember this "short term" is most likely the next few trading days, assuming the sellers are successful to some small degree. How are you to know when to buy your shares back assuming you sell Monday morning? Can you expect a timely and gracious message or phone call to tell YOU the bottom has been made -- hurry -- buy now?